ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
34 announcements
Neuland Laboratories reported annual financial results and recommended a ₹34 per share dividend. It also announced a ₹143.4 Crore capacity expansion at its Unit 1 facility.
Neuland Laboratories Limited has scheduled a Board Meeting for May 12, 2026, to consider audited financial results for the year ended March 31, 2026, and a final dividend. The trading window for designated persons is closed from April 1 to May 14, 2026.
Neuland Laboratories Ltd has scheduled a Board Meeting on May 12, 2026, to approve the audited financial results for the quarter and year ended March 31, 2026. The board will also consider recommending a final dividend for FY 2025-26. Consequently, the trading window for company shares remains closed until 48 hours post-declaration.
Neuland Laboratories Ltd submitted an Annual Compliance Certificate for Davuluri Ownership Trust for FY 2025-26. Issued by M/s. B Srinivasa Rao & Co., the certificate confirms compliance with the SEBI Exemption Order dated January 3, 2025. This is a routine regulatory filing for information and record purposes.